Clinical Trial Update: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating obinutuzumab with bendamustine in relapsed/refractory chronic lymphocytic leukemia has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-11-26